1 Drug Health Services, Western Health, Footscray, VIC, Australia.
2 Youth Support + Advocacy Service, Fitzroy, VIC, Australia.
Aust N Z J Psychiatry. 2017 Sep;51(9):876-885. doi: 10.1177/0004867417714878. Epub 2017 Jun 22.
Attention deficit hyperactivity disorder and stimulant use disorder commonly co-exist, and appropriate treatments have not been well established.
To provide guidance for treatment of co-existing attention deficit hyperactivity disorder and stimulant use disorder.
A systematic review of published English articles using MEDLINE, EMBASE, CINAHL, PsycINFO and Cochrane, utilising consistent search terms.
Randomised controlled trials, comparing any treatment arm with a control group, for participants meeting Diagnostic and Statistical Manual of Mental Disorders or equivalent criteria for both attention deficit hyperactivity disorder and stimulant use disorder.
Eight trials were identified for inclusion in this review. Four of eight studies showed improvement in attention deficit hyperactivity disorder outcome measures compared with placebo. Two of six studies that reported substance use outcomes showed improvement in treatment arms compared with placebo. Studies to show effect tended to be those with the highest treatment dosage.
Evidence for the efficacy of treatment of patients with comorbid stimulant use disorder and attention deficit hyperactivity disorder is limited. Promising outcomes need replication in further studies utilising higher treatment dosage.
注意缺陷多动障碍和兴奋剂使用障碍通常同时存在，且尚未确立合适的治疗方法。
为共病注意缺陷多动障碍和兴奋剂使用障碍的治疗提供指导。
使用 MEDLINE、EMBASE、CINAHL、PsycINFO 和 Cochrane 中的已发表英文文章进行系统评价，使用一致的搜索词。
随机对照试验，将任何治疗组与对照组进行比较，纳入符合《精神障碍诊断与统计手册》或等效标准的同时患有注意缺陷多动障碍和兴奋剂使用障碍的参与者。
本综述纳入了 8 项研究。8 项研究中的 4 项显示与安慰剂相比，在注意缺陷多动障碍结局测量方面有所改善。6 项报告物质使用结果的研究中有 2 项显示治疗组与安慰剂相比有所改善。显示疗效的研究往往是那些使用最高治疗剂量的研究。
治疗共病兴奋剂使用障碍和注意缺陷多动障碍患者的疗效证据有限。需要进一步使用更高治疗剂量的研究来复制有前途的结果。
